Patent ID: 11891450
Assignee: FORTY SEVEN, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of effectively treating or reducing cancer burden with an overall response rate of at least 40% in human subjects, wherein the human subjects have Non-Hodgkin's lymphoma (NHL) and are refractory to rituximab, comprising:
(a) determining, before administering steps, that the human subjects are refractory to rituximab;
(b) selecting the refractory subjects for treatment;
(c) administering to the refractory subjects for four weeks a first cycle comprising (1) a priming dose of anti-CD47 antibody at about 1 mg of antibody per kg of body weight at time 0 (T0), (2) a dose of at least 30 mg of the anti-CD47 antibody per kg of body weight once every week beginning one week after TO, and (3) a dose of 375 mg/m2 of anti-CD20 antibody once every week; and
(d) administering to the refractory subjects for four weeks a second cycle comprising (1) a dose of at least 30 mg of the anti-CD47 antibody per kg of body weight once every two weeks, and (2) a dose of 375 mg/m2 of the anti-CD20 antibody once every four weeks;
thereby effectively treating or reducing cancer burden in the refractory subjects such that an overall response rate (ORR) of at least 40% is achieved.